The U.S. International Trade Commission (ITC) will begin an investigation into Eli Lilly’s complaint that Hospira Inc. and affiliated pharmaceutical companies infringed on Lilly’s patent by importing and selling generic versions of the cancer drug, Gemzar®. The complaint was first filed after Hospira launched a generic version of Lilly’s Gemzar®. The ITC will look into whether Hospira and the other companies have violated section 337 of the Tariff Act of 1930, which restrict importing infringing products. Lilly is represented by Finnegan.